NO20051663L - Fremgangsmater for behandling av neurodegenerasjon - Google Patents

Fremgangsmater for behandling av neurodegenerasjon

Info

Publication number
NO20051663L
NO20051663L NO20051663A NO20051663A NO20051663L NO 20051663 L NO20051663 L NO 20051663L NO 20051663 A NO20051663 A NO 20051663A NO 20051663 A NO20051663 A NO 20051663A NO 20051663 L NO20051663 L NO 20051663L
Authority
NO
Norway
Prior art keywords
methods
treating neurodegeneration
disease
alpha
treating
Prior art date
Application number
NO20051663A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel W Gil
Larry A Wheeler
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20051663L publication Critical patent/NO20051663L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20051663A 2002-10-08 2005-04-04 Fremgangsmater for behandling av neurodegenerasjon NO20051663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41704902P 2002-10-08 2002-10-08
PCT/US2003/031809 WO2004032913A1 (en) 2002-10-08 2003-10-07 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
NO20051663L true NO20051663L (no) 2005-05-31

Family

ID=32093954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051663A NO20051663L (no) 2002-10-08 2005-04-04 Fremgangsmater for behandling av neurodegenerasjon

Country Status (19)

Country Link
US (1) US20040138312A1 (de)
EP (1) EP1549305B1 (de)
JP (2) JP4724421B2 (de)
KR (1) KR20050050124A (de)
CN (1) CN100431536C (de)
AT (1) ATE429216T1 (de)
AU (2) AU2003282758A1 (de)
BR (1) BR0314540A (de)
CA (1) CA2501347A1 (de)
DE (1) DE60327335D1 (de)
ES (1) ES2322954T3 (de)
IL (1) IL167849A (de)
MX (1) MXPA05003664A (de)
NO (1) NO20051663L (de)
NZ (1) NZ539328A (de)
PL (1) PL216373B1 (de)
RU (1) RU2330649C2 (de)
WO (1) WO2004032913A1 (de)
ZA (1) ZA200502744B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007105203A2 (en) * 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2010077586A1 (en) * 2008-12-08 2010-07-08 Allergan, Inc. N-(1-phenyl-2-arylethyl)-4,5-dihydro-3h-pyrrol-2-amine compounds as subtype selective modulators of alpha2b or alpha2b and alpha2c adrenoceptors
CN110337290A (zh) 2016-12-31 2019-10-15 比奥克斯塞尔医疗股份有限公司 舌下右旋美托咪啶用于治疗激越的用途
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
EP3999058A4 (de) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. Behandlungsschemata für nicht-sedierendes dexmedetomidin
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
CN1284066A (zh) * 1997-12-04 2001-02-14 阿勒根销售公司 对α2B或2B/2C肾上腺素能受体具有激动剂样活性的取代咪唑衍生物
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
BR0109317A (pt) * 2000-07-14 2003-06-17 Allergan Inc Composições contendo componentes agonistas alfa-2-adrenérgicos
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
DE60327335D1 (de) 2009-06-04
ZA200502744B (en) 2006-02-22
ES2322954T3 (es) 2009-07-02
PL376346A1 (en) 2005-12-27
KR20050050124A (ko) 2005-05-27
CA2501347A1 (en) 2004-04-22
CN1703213A (zh) 2005-11-30
AU2009238370A1 (en) 2009-12-17
WO2004032913A1 (en) 2004-04-22
ATE429216T1 (de) 2009-05-15
JP2006504739A (ja) 2006-02-09
AU2009238370B2 (en) 2011-07-21
US20040138312A1 (en) 2004-07-15
AU2003282758A1 (en) 2004-05-04
PL216373B1 (pl) 2014-03-31
EP1549305B1 (de) 2009-04-22
EP1549305A1 (de) 2005-07-06
NZ539328A (en) 2007-01-26
MXPA05003664A (es) 2005-06-08
BR0314540A (pt) 2005-07-26
CN100431536C (zh) 2008-11-12
RU2005114504A (ru) 2005-10-27
JP2011057700A (ja) 2011-03-24
JP4724421B2 (ja) 2011-07-13
RU2330649C2 (ru) 2008-08-10
HK1081880A1 (zh) 2006-05-26
IL167849A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
MXPA04003103A (es) Derivados de bencimidazolidinona como agentes muscarinicos.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
DE60334015D1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
DK1220852T3 (da) Substituerede diazepaner
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
NO20056116L (no) Tiowolframatanaloger og anvendelse av slike
DK1223930T3 (da) Behandling af dyskinesi
BR0314541A (pt) Tratamento de demência e doença de parkinson